MAIA Biotechnology
MAIA
6 hedge funds and large institutions have $247K invested in MAIA Biotechnology in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
2.06% less ownership
Funds ownership: 2.71% → 0.65% (-2.1%)
76% less capital invested
Capital invested by funds: $1.04M → $247K (-$797K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$84.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$11.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.78K |
| 4 |
BlackRock
New York
|
+$542 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$878K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$7 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CWM
1
Centric Wealth Management
Chicago,
Illinois
| $139K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $71K | +$84.9K | +20,650 | New |
|
|
3
BlackRock
New York
| $13.9K | +$542 | +132 | +3% |
|
|
4
UBS Group
Zurich,
Switzerland
| $13.7K | +$3.78K | +919 | +30% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $9K | +$11.1K | +2,706 | New |
|
6
Wells Fargo
San Francisco,
California
| $48 | – | – | – |
|
|
LCM
7
Lynwood Capital Management
Toronto,
Ontario, Canada
| – | -$878K | -250,000 | Closed |
|
|
8
Bank of America
Charlotte,
North Carolina
| – | -$7 | -2 | Closed |
|
MAIA Hedge Fund Activity: Q1 2023 in Review
6 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q1 2023, worth a combined $247K — down 76% from $1.04M a quarter earlier.
Fund positioning in MAIA was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $84.9K. The largest seller was Lynwood Capital Management, exiting entirely with an estimated $878K sold.
- 6 institutional investors held MAIA Biotechnology (MAIA) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $247K of MAIA Biotechnology stock for Q1 2023, down 76% quarter-over-quarter.
- 2 funds opened new MAIA Biotechnology positions in Q1 2023 and 2 closed out, a net change of 0 holders.
- The largest MAIA Biotechnology buyer in Q1 2023 was Renaissance Technologies, an estimated $84.9K added.
- The largest MAIA Biotechnology seller in Q1 2023 was Lynwood Capital Management, an estimated $878K sold.
Based on aggregated 13F filings for Q1 2023.